19 / 23
ALK
translocaƟon
EGFR
mutaƟon
GefiƟnib (I,A), AfaƟnib(I,A)
ErloƟnib(I,A) +/-bevacizumab
(I,B), DacomiƟnib (I,A)
#
OsimerƟnib (I,A)
BRAF
V600E
mutaƟon
Dabrafenib plus
TrameƟnib (II,A)
AlecƟnib (I,A)
BrigaƟnib (I,B)
#
CrizoƟnib (I,A)
CeriƟnib (I,A)
AlecƟnib* (I,A)
CeriƟnib* (I, A)
BrigaƟnib* (II,A)
#
ROS
translocaƟon
CrizoƟnib (III,A)
Not EMA approved
*In paƟents who received crizoƟnib previously
**In paƟents who did not receive first-line osimerƟnib
& In paƟents with oligo-progression consider local strategies (surgery or SBRT) and conƟnue with targeted therapy (II,A)
at PD
&
at PD
&
OsimerƟnib** (I,A)
T790M+
PlaƟnum-based chemotherapy (I,A)
T790M-
Tissue re-biopsy
T790M+
T790M-
Liquid biopsy (T790M status)
LorlaƟnib (II
,
A)
#
PlaƟnum-based chemotherapy
at PD
&